Extended Data Fig. 3: Development of a small molecule inactivator of mitochondrial copper(II).
From: A druggable copper-signalling pathway that drives inflammation
a, Flow cytometry of MDM treated with ATTM (10 µM, n = 5 donors), D-Pen (250 µM, n = 5 donors), EDTA (500 µM, n = 5 donors) or Trien (200 µM, n = 5 donors). b, Structural analysis of biguanide-based copper(II) complexes by molecular modeling. Top and side views highlight distinct geometries of Cu(Met)2, Cu–LCC-12 and Cu–LCC-4,4. c, HRMS of Cu(Met)2 and Cu–LCC-4,4. d, HRMS of LCC-12 in the presence of metals as indicated. e, UV absorbance spectra of LCC-12 (5 µM) titrated with a solution of copper(II). f, Picture of aq. solutions of Met, LCC-12, CuCl2 and corresponding mixtures. g, Western blots of AMPKα and phosphorylated AMPKα (p-AMPKα) in MDM treated with LCC-12 or Met (n = 6 donors). For a and g Kruskal-Wallis test with Dunn’s post-test. Box plots: boxes represent interquartile range and median, and whiskers indicate the minimum and maximum values. Each colored dot represents a distinct donor for a given panel.
